5
Orphan Designations
0 approved, 5 designated
0
FDA Approvals
2
Active Trials
200 recruiting
8
Rare Diseases
across 20 areas
0
News (30d)
Quiet
Tango Therapeutics, Inc. is a company with 5 orphan drug designations across 8 rare diseases. Active clinical trials in 2 indications.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| bone neoplasm | Small molecule inhibitor of PRMT5 | Des.TrialAppr. |
| brain neoplasm | - | Des.TrialAppr. |
| diaphyseal medullary stenosis-bone malignancy syndrome | small molecule inhibitor of PRMT5 (protein arginine methyl transferase 5)Small molecule inhibitor of PRMT5 | Des.TrialAppr. |
| disorder of polyamine metabolism | small molecule inhibitor of PRMT5 (protein arginine methyl transferase 5)Small molecule inhibitor of PRMT5 | Des.TrialAppr. |
| malignant glioma | small molecule inhibitor of protein arginine methyl transferase 5 (PRMT5)Small molecule inhibitor of PRMT5 (protein arginine methyl transferase 5) | Des.TrialAppr. |
| malignant peripheral nerve sheath tumor | Small molecule inhibitor of PRMT5 (protein arginine methyl transferase 5) | Des.TrialAppr. |
| sarcoma | - | Des.TrialAppr. |
| spastic ataxia 4 | small molecule inhibitor of PRMT5 (protein arginine methyl transferase 5) | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
23
overlap in 2+ diseases
0/8
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
23
overlap in 2+ diseases
0/8
candidate diseases
0
avg importance: 0
0
affecting portfolio